Key Drivers
- Margin Compression
- Debt Surge
- Liquidity Adequate
AIAI Summary
ALKS is now an acquisition-driven, leveraged execution story rather than a straightforward profitable neuroscience play: investors should wait for margin and EBITDA recovery toward 2026 guidance to validate that Lumryz/Avadel benefits and alixorexton upside can support $1.57B of debt, as weak interest coverage leaves little room for delays.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Margin Compression
- •Debt Surge
- •Liquidity Adequate
ALKS shifted from strong 2025 profitability and net cash to sharply weaker margins, heavy leverage, and stretched valuation in 2026, warranting caution despite adequate liquidity and positive free cash flow.
Price Behavior
Key Price Behavior Insights:
- •Lower highs
- •Sharp selloff
- •Oversold momentum
ALKS is in a bearish last-month trend, with oversold momentum suggesting rebound potential, but remain defensive unless it holds $43.39 support and reclaims $46.10 resistance.
Sharp 7.1% one-day drop on 2026-09-18
Sentiment & News
Key News Insights:
- •Alixorexton Progress
- •Analyst Upgrade
- •Institutional Buying
Alkermes' positive alixorexton trial data, Buy upgrade, and rising institutional support reinforce a constructive growth outlook despite insider selling and ongoing GAAP losses.
The news flow is broadly positive for ALKS, supporting sentiment around pipeline-driven growth and commercialization potential
Similar Companies in Healthcare
Other companies in the same sector with AI ratings